Mölnlycke Health Care Market Research Report

Company Overview

General Information

Name: Mölnlycke Health Care

Mission: Revolutionise care for people and planet by improving the quality of life for patients and caregivers while reducing the environmental footprint of healthcare.

Founded: 1849

Founded by: No information is available

Key People:

Zlatko Rihter (CEO)

Guillaume Joucla (Appointed CFO as of January 2025)

Headquarters: Gothenburg, Sweden

Number of Employees: Approximately 8,700

Financial Information

Revenue: EUR 1,924 million in 2023, with an 8% increase in constant currency rates.

EBITDA: EUR 545 million in 2023, reflecting a 14% growth.

Business Areas

Mölnlycke Health Care is known for its expertise in the following areas:

Wound Care: Leading global provider of wound care products and therapy-based solutions.

Operating Room Solutions: Provides solutions for improved operating room efficiency and sustainability.

Gloves: Innovative and sustainable gloves solutions.

Antiseptics: Reduces risk of infections throughout patient care journeys.

Products

Product Offerings

1. Wound Care Products:

Products aimed at treating a variety of wounds including chronic wounds and surgical sites.

2. Operating Room Solutions:

Offers ProcedurePak® trays that reduce setup time and packaging waste.

3. Gloves:

Biogel® gloves known for production efficiency and safety in surgical environments.

4. Antiseptics:

Products like Hibiwash® for patient skin decolonization.

Key Features

Safetac® Technology: A silicone adhesive that reduces pain and minimizes skin trauma during dressing changes.

ProcedurePak® Trays: Provides a sterile tray with necessary components to enhance efficiency and safety.

Recent Developments

Investments and Acquisitions

January 2025: Invested USD 8 million in Siren for diabetic foot ulcer management solutions.

October 2024: Acquired P.G.F. Industry Solutions GmbH, manufacturer of Granudacyn® solutions for wound cleansing.

July 2024: Invested USD 15 million in MediWound Ltd focusing on enzymatic therapeutics.

Awards and Recognitions

November 2024: Won Swedish Sustainability Tech award for sustainable healthcare innovations.

September 2024: Received Platinum medal from EcoVadis, placing Mölnlycke in the top 1% for sustainability ratings.

Strategic Partnerships

September 2024: Partnered with Ondine Biomedical for Steriwave® technology in the UK, EU, and Middle East.

November 2024: Collaborated with Operation Smile to establish a cleft care center in the Philippines.

Product Developments

Launched Mepilex® Up and upgraded Mepilex® Border Post-Op products globally.

Registration of Hibiwash® formula, color and fragrance-free.

Sustainability Initiatives

Committed to 100% fossil-free electricity by end of 2024.

Implemented various strategies to achieve a 20% reduction in overall absolute greenhouse gas emissions compared to the 2021 baseline.

Organisational Changes

Appointed Guillaume Joucla as Chief Financial Officer effective January 2025, succeeding Susanne Larsson.

Mölnlycke Health Care continues to expand its global reach through strategic acquisitions, partnerships, and by thus driving its mission to revolutionise patient care with innovative medical solutions.